[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 2002

Improving Clinical TrialsAmerican Society of Clinical Psychopharmacology Recommendations

Author Affiliations

From the New York State Psychiatric Institute, New York (Drs Klein and Endicott); University of Pittsburgh Medical Center and Western Psychiatric Institute and Clinic, Pittsburgh, Pa (Dr Thase); Clinical Insights, Glen Burnie, Md (Dr Adler); Stanford University School of Medicine, Stanford, Calif (Dr Glick); Quintiles Inc, San Diego, Calif, and the University of California, Irvine (Dr Kalali); Vela Pharmaceuticals, Lawrenceville, NJ (Dr Leventer); Psychopharmacology Research of Princeton, Princeton, NJ (Dr Mattes); the American Society of Clinical Psychopharmacology Inc and the National Foundation for Depressive Illness, New York (Mr Ross); and the University of California, Los Angeles (Dr Bystritsky). Although all authors have extensive contacts with industry, the focus of this article is methodological.

Arch Gen Psychiatry. 2002;59(3):272-278. doi:10.1001/archpsyc.59.3.272

The major purpose of this American Society of Clinical Psychopharmacology-sponsored meeting was to identify strategies for more efficiently detecting clinical drug effects, thus reducing the economic and scientific risks of investigating new chemical entities in psychiatric disorders. The meeting consisted of presentations and discussions by experts who repeatedly had difficulty pursuing scientific, public health–relevant goals. Many approaches to improving the detection of potentially beneficial agents were reviewed. In this article, we discuss technically feasible study improvements. The scope of inquiry included identifying means of shifting institutional and regulatory assumptions and processes, even to the point of seeking appropriate national incentives.